Edgewise says EDG-7500 posts positive 12-week Phase 2 data in hypertrophic cardiomyopathy trial

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTX

0.00
  • Edgewise Therapeutics released positive top-line results from a 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy.
  • Findings have been presented as top-line data; a webcast is scheduled for today to review the results.
  • Patients showed broad improvements in heart function, symptoms, and daily functioning across obstructive and nonobstructive disease, supporting Phase 3 advancement.
  • Safety profile remained favorable with no meaningful signs of weakened pumping function; the drug was generally well tolerated.
  • Phase 3 program initiation is targeted for Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606160700PR_NEWS_USPR_____LA84622) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.